Novo Nordisk Chooses IBM's Watson to Harness Diabetes Drug Data
- Companies to explore possibilities for improved diabetes care
- Agreement adds to others between drugmakers and Google, Fitbit
This article is for subscribers only.
The world’s biggest insulin maker is teaming up with a unit of IBM to crunch data on how people are managing their diabetes, the latest collaboration of its kind between pharmaceutical and technology companies.
Novo Nordisk A/S plans to gather information from patients using its treatments and devices to develop more advanced ways to keep the disease in check, the Danish company said in a statement Thursday. Novo’s partner Watson, International Business Machine Corp.’s cognitive computing platform, can process vast amounts of data to uncover user patterns and suggest possibilities for improved diabetes care.